Powerful MHC-class II peptides derived from survivin
The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
1. An isolated nucleic acid sequence encoding: a peptide consisting of SEQ ID NO: 3.
2. An expression vector comprising the isolated nucleic acid sequence of claim 1 .
3. An isolated host cell comprising the expression vector of claim 2 .
4. The isolated host cell of claim 3 , wherein said host cell is an antigen presenting cell.
5. The isolated host cell of claim 3 , wherein said host cell is a dendritic cell.